The role of molecular biomarker CDKN-2A in early diagnosis of colorectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Y. Ten
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors Y. Ten1, S. Abdujapparov1, Y. Ziyaev1, A. Abdujapparov2
  • 1Republican Cancer center of Uzbekistan, Tashkent, Uzbekistan, /
  • 2Tashkent Medical Academy, Tashkent, Uzbekistan, /


Polyps are considered as obligate precancerous disease. Different authors consider that percent of malignization ranges from 20% in single polyps to 95% in diffuse polyposis. Current research examines the results of the early diagnosis of colon cancer by using the biomarker CDKN2A for development of molecular-biological methods of prognostication. Using a set of early diagnostic measures for the detection of colon cancer clinical and medical history and their correlation with the molecular-biological indicators were studied. It is also planned to develop an effective system for development prognostication of CRC and the formation of \"risk groups\" for evidence-based counseling for families which are highly predisposed for colorectal cancer.